Connie Lee Batlevi

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

34h-index4.6kcitations244works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(159), CAR-T cell therapy research(75), Chronic Lymphocytic Leukemia Research(71), Viral-associated cancers and disorders(24), Cancer Genomics and Diagnostics(23)

Publications244 total

Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma
Haematologica·2025Open Access
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology·2025
Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study
Blood·2025
A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial
Blood·2025Open Access
Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy
Blood·2025Open Access
Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX
Blood·2025Open Access
Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma
Blood·2025Open Access
Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review
Blood·2025
Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities
Blood·2025
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
HemaSphere·2025Open Access
Antibody Titers of Vaccine-Preventable Pathogens at 1 Year Post CD19 CAR-T Cell Therapy
Transplantation and Cellular Therapy·2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Journal of Clinical Oncology·2025· 2 citedOpen Access
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology·2025· 9 citedOpen Access
ORAL ABSTRACT: MCL-1493 Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL)
Clinical Lymphoma Myeloma & Leukemia·2025
MCL-1493: Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL)
Clinical Lymphoma Myeloma & Leukemia·2025· 2 cited
ORAL ABSTRACT: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO Trial
Clinical Lymphoma Myeloma & Leukemia·2025
ABCL-475: 5-Year Analysis of the POLARIX Study: Prolonged Follow-Up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO Trial
Clinical Lymphoma Myeloma & Leukemia·2025
ABCL-1492: Mosunetuzumab Plus Polatuzumab Vedotin (MPola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO Trial
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MCL-1493 Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL)
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 13Next →

Frequent Co-authors

Anas Younes(19), Gunjan L. Shah(16), M. Lia Palomba(16), Miguel‐Angel Perales(16), Michael Scordo(15), Craig S. Sauter(15), Gilles Salles(14), Paul A. Hamlin(14), Matthew J. Matasar(14), Andrew D. Zelenetz(14), Parastoo B. Dahi(13), Alison J. Moskowitz(13), Ariela Noy(13), Anita Kumar(12), David J. Straus(12), Sean M. Devlin(11), Sergio Giralt(11), Steven M. Horwitz(11), Venkatraman Seshan(11), Jae H. Park(10)